XAIR
Beyond Air, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.53
−1.67%Aug 31, 2026, 12:00 UTC
The U.S. Food and Drug Administration granted Breakthrough Device Designation to Beyond Air's LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease.
Source:Aug 25, 2026, 11:00 UTC
Beyond Air entered a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries in exchange for equity and milestone payments.
Source:Aug 13, 2026, 11:00 UTC
Beyond Air reported financial results for the quarter ended June 30, 2026, with revenue of $1.8 million, and reaffirmed revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027.
Jul 31, 2026, 00:00 UTC
Beyond Air, Inc. entered into a private placement offering of common stock, pre-funded warrants, and Series A and Series B warrants, raising approximately $10.2 million upfront and up to $30.1 million if all warrants are exercised.